Oncology Update: Breakthrough Trials, Drug Approvals & New Therapies

This week in oncology: Merck and Daiichi Sankyo begin Phase 3 trial for ifinatamab deruxtecan in esophageal squamous cell carcinoma. PharmaMar submits a marketing application for lurbinectedin and atezolizumab in small cell lung cancer. Zai Lab’s ZL-1310 receives FDA Fast Track for small cell lung cancer. Health Canada approves Tagrisso for Stage III EGFR-mutant NSCLC. Kelun-Biotech files for sacituzumab tirumotecan in breast cancer. Roche’s inavolisib recommended for PIK3CA-mutant breast cancer. Gilead’s Trodelvy shows positive results in triple-negative breast cancer. Clarity launches Phase 3 prostate cancer trial.

Видео Oncology Update: Breakthrough Trials, Drug Approvals & New Therapies канала LucidQuest